Ark postpones LSE (London Stock Exchange) float:
This article was originally published in Clinica
Executive Summary
Unusual market conditions" have prompted UK biotechnology company Ark Therapeutics to postpone its flotation on the London Stock Exchange. The London-based company, which develops medical products and pharmaceuticals aimed at vascular disease and cancer, had planned to raise up to $57 million in the offering (see Clinica No 1003, p 14). CEO Nigel Parker stressed that the company had been "extremely well received" at all investor meetings and that it intended to return to the capital markets when conditions were more favourable.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.